RxDoctor Payments Data

Cheryl Lummis, APRN

Adult Health · Mexico, MONPI 1962438762

Payments from drug & device makers

$4,695in general payments, 2019–2025

Across 330 payments — averaging $14.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$741
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$544
  • AbbVie$533
  • Alkermes, Inc.$261
  • Teva Pharmaceuticals USA, Inc.$257
  • Otsuka America Pharmaceutical, Inc.$244
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,695 in reported general payments places this provider in the 85th percentile of 555 adult health providers in Missouri.

See all adult health providers in Missouri

Medicare billing

Part B allowed, 2024
$1,653
Medicare patients
20
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$55,512
TrulicityDulaglutide31$29,623
LinzessLinaclotide28$26,959
EliquisApixaban32$24,454
JardianceEmpagliflozin22$19,030
RybelsusSemaglutide17$16,650
Combivent RespimatIpratropium/Albuterol Sulfate19$12,996
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$9,421
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$8,656
FarxigaDapagliflozin Propanediol14$8,203
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$6,570
XareltoRivaroxaban11$6,162
Humalog Kwikpen U-100Insulin Lispro26$5,984
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro18$5,530
Novolog FlexpenInsulin Aspart24$5,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$16$75,59780 claims
Boehringer IngelheimJardiance, Combivent Respimat$44$32,02641 claims
Lilly USA, LLCTrulicity$160$29,62331 claims
AbbVieLinzess$533$26,95928 claims
Indivior Inc.Suboxone$82$9,42112 claims
AstraZenecaFarxiga$211$8,20314 claims
Johnson & JohnsonXarelto$57$6,16211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 555 adult health providers in Missouri.

Other adult health in Mexico

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →